Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia

被引：0
|
作者：
Xuejie Jiang
Ling Jiang
Jiaying Cheng
Fang Chen
Jinle Ni
Changxin Yin
Qiang Wang
Zhixiang Wang
Dan Fang
Zhengshan Yi
Guopan Yu
Qingxiu Zhong
Bing Z. Carter
Fanyi Meng
机构：
[1] Nanfang Hospital,Department of Hematology
[2] Southern Medical University,Department of Hematology
[3] Kanghua Hospital,Section of Molecular Hematology and Therapy, Department of Leukemia
[4] The University of Texas MD Anderson Cancer Center,undefined
来源：
Journal of Translational Medicine | / 19卷
关键词：
EZH2; Chidamide; Leukemia; Chemosensitivity; Smo/Gli-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway
    Pingyu Zhang
    Xianbin Yang
    Xiaoyan Ma
    Davis R Ingram
    Alexander J Lazar
    Keila E Torres
    Raphael E Pollock
    Molecular Cancer, 14
  • [42] Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway
    Zhang, Pingyu
    Yang, Xianbin
    Ma, Xiaoyan
    Ingram, Davis R.
    Lazar, Alexander J.
    Torres, Keila E.
    Pollock, Raphael E.
    MOLECULAR CANCER, 2015, 14
  • [43] Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
    Hao Wang
    Yu-chen Liu
    Cheng-ying Zhu
    Fei Yan
    Meng-zhen Wang
    Xiao-su Chen
    Xiao-kai Wang
    Bao-xu Pang
    Yong-hui Li
    Dai-hong Liu
    Chun-ji Gao
    Shu-jun Liu
    Li-ping Dou
    Journal of Experimental & Clinical Cancer Research, 39
  • [44] MOLECULAR ANALYSIS OF IDH2, DNMT3A, EZH2, WT1 AND CBL MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH CBFB GENE REARRANGEMENT
    Kim, I. S.
    Shin, H. J.
    Lee, E. Y.
    Kim, H. J.
    Won, J. H.
    Bang, S. M.
    Kim, H.
    HAEMATOLOGICA, 2014, 99 : 561 - 561
  • [45] Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
    Caner Saygin
    Cassandra Hirsch
    Bartlomiej Przychodzen
    Mikkael A. Sekeres
    Betty K. Hamilton
    Matt Kalaycio
    Hetty E. Carraway
    Aaron T. Gerds
    Sudipto Mukherjee
    Aziz Nazha
    Ronald Sobecks
    Christopher Goebel
    Donna Abounader
    Jaroslaw P. Maciejewski
    Anjali S. Advani
    Blood Cancer Journal, 8
  • [46] Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate-Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1
    Saygin, Caner
    Hirsch, Cassandra M.
    Przychodzen, Bartlomiej
    Sekeres, Mikkael A.
    Hamilton, Betty K.
    Kalaycio, Matt
    Carraway, Hetty E.
    Gerds, Aaron T.
    Mukherjee, Sudipto
    Nazha, Aziz
    Sobecks, Ronald
    Goebel, Christopher
    Abounader, Donna M.
    Maciejewski, Jaroslaw P.
    Advani, Anjali S.
    BLOOD, 2017, 130
  • [47] Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
    Saygin, Caner
    Hirsch, Cassandra
    Przychodzen, Bartlomiej
    Sekeres, Mikkael A.
    Hamilton, Betty K.
    Kalaycio, Matt
    Carraway, Hetty E.
    Gerds, Aaron T.
    Mukherjee, Sudipto
    Nazha, Aziz
    Sobecks, Ronald
    Goebel, Christopher
    Abounader, Donna
    Maciejewski, Jaroslaw P.
    Advani, Anjali S.
    BLOOD CANCER JOURNAL, 2018, 8
  • [48] Combined targeting of chromatin modifying enzymes LSD1, histone deacetylases (HDACs) and EZH2 has superior efficacy against human acute myeloid leukemia cells
    Fiskus, Warren C.
    Sharma, Sunil
    Rao, Rekha
    Balusu, Ramesh
    Venkannagari, Sreedhar
    Hembruff, Stacey
    Abhyankar, Sunil
    McGuirk, Joseph
    Aljitawi, Omar
    Ganguly, Siddhartha
    Bearss, David
    Bhalla, Kapil N.
    CANCER RESEARCH, 2012, 72
  • [49] TREATMENT WITH PAN DEACETYLASE (DAC) INHIBITOR PANOBINOSTAT (LBH589) DEPLETES EZH2 AND DNMT1, DEREPRESSES JUNB AND SENSITIZES ACUTE MYELOID LEUKEMIA CELLS TO DECITABINE
    Fiskus, W.
    Wang, Y.
    Rao, R.
    Atadja, P.
    Bhalla, K. N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 9 - 9
  • [50] Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro
    Wellbrock, Jasmin
    Koehler, Julian M.
    Wagner, Katharina
    Latuske, Emily
    Stamm, Hauke
    Vettorazzi, Eik
    Vohwinkel, Gabi
    Klokow, Marianne
    Kuhling-Thees, Roswitha
    Loges, Sonja
    Amling, Michael
    Bokemeyer, Carsten
    Heuser, Michael
    Krauter, Juergen
    Fiedler, Walter
    BLOOD, 2013, 122 (21)
12345